Novavax Inc At Devex UNGA 76 Transcript
Hello, everyone. I'm Jenny Lei Ravelo, Senior Global Health Reporter for Devex. Thank you so much for tuning into our series of events around the UN General Assembly. Access to COVID-19 vaccines continues to be a hot topic and rightly so. Billions of people around the world still have not received at least one dose of the COVID vaccine. There continues to be a huge demand. And despite estimates of vaccines being producing over 1 billion a month, access to them, particularly in low and middle income countries, remains a challenge. But there are more vaccines coming, and one of them is actually a COVID-19 vaccine developed by Novavax, an American biotech company that has decades of experience developing vaccines for serious infectious diseases.
In June, Novavax grabbed headlines after releasing efficacy data from a Phase III clinical trial in the U.S., showing those COVID-19 vaccine has 90% overall efficacy, including 100% protection against moderate and severe illness.
And so I'm pleased to be joined today by Mr. John Trizzino, Novavax' Executive Vice President, Chief
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
